Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | STS | P08842 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | TGM1 | P22735 | 1/20 | 0.37 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177482 | 0.87 | MEN1 (0.47) | MEN1KMT2ASTSMAPTMAPK1 | |
| SCHEMBL21184106 | 0.87 | MEN1 (0.47) | MEN1KMT2ASTSMAPTMAPK1 | |
| SCHEMBL21184107 | 0.86 | MEN1 (0.46) | MEN1KMT2ASTSMAPTMAPK1 | |
| SCHEMBL21184067 | 0.83 | HRH3 (0.38) | MEN1KMT2AMAPTMAPK1HTT | |
| SCHEMBL21184046 | 0.83 | SLC6A2 (0.37) | MEN1KMT2AMAPTNPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30354183 | 0.82 | SLC6A2 (0.39) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL24090495 | 0.80 | MEN1 (0.56) | MEN1KMT2ASTSMAPTMAPK1 | |
| SCHEMBL24090494 | 0.79 | MEN1 (0.42) | MEN1KMT2ASTSMAPTMAPK1 | |
| SCHEMBL24090510 | 0.79 | MEN1 (0.42) | MEN1KMT2ASTSMAPTMAPK1 | |
| SCHEMBL21184112 | 0.79 | MEN1 (0.39) | MEN1KMT2ASTSMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | AURIGENE ONCOLOGY LIMITED (IN) | 2023-04-25 | — | — | US | disclosed |
| US-20210379055-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-12-09 | — | — | US | disclosed |
| WO-2019142126-A1 | SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | MEN1 1649/4885KMT2A 2821/4885STS 2963/4885 |
| US-20210379055-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | MEN1 1649/4885KMT2A 2821/4885STS 2963/4885 |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | MCL1, ROS1, MKI67 | MEN1 1649/4885KMT2A 2821/4885STS 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.